Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 12 |
| List of Tables | 11 | 2 |
| List of Figures | 13 | 1 |
| Introduction | 14 | 1 |
| Global Markets Direct Report Coverage | 14 | 1 |
| Recurrent Glioblastoma Multiforme (GBM) Overview | 15 | 1 |
| Therapeutics Development | 16 | 2 |
| Pipeline Products for Recurrent Glioblastoma Multiforme (GBM) Overview | 16 | 1 |
| Pipeline Products for Recurrent Glioblastoma Multiforme (GBM) Comparative Analysis | 17 | 1 |
| Recurrent Glioblastoma Multiforme (GBM) Therapeutics under Development by Companies | 18 | 3 |
| Recurrent Glioblastoma Multiforme (GBM) Therapeutics under Investigation by Universities/Institutes | 21 | 1 |
| Recurrent Glioblastoma Multiforme (GBM) Pipeline Products Glance | 22 | 3 |
| Late Stage Products | 22 | 1 |
| Clinical Stage Products | 23 | 1 |
| Early Stage Products | 24 | 1 |
| Recurrent Glioblastoma Multiforme (GBM) Products under Development by Companies | 25 | 4 |
| Recurrent Glioblastoma Multiforme (GBM) Products under Investigation by Universities/Institutes | 29 | 1 |
| Recurrent Glioblastoma Multiforme (GBM) Companies Involved in Therapeutics Development | 30 | 43 |
| AbbVie Inc | 30 | 1 |
| Agenus, Inc. | 31 | 1 |
| Amgen Inc. | 32 | 1 |
| AngioChem Inc. | 33 | 1 |
| Apogenix GmbH | 34 | 1 |
| Arog Pharmaceuticals, Inc. | 35 | 1 |
| Axelar AB | 36 | 1 |
| BeiGene, Ltd. | 37 | 1 |
| Boehringer Ingelheim GmbH | 38 | 1 |
| Boston Biomedical, Inc. | 39 | 1 |
| Bristol-Myers Squibb Company | 40 | 1 |
| Cantex Pharmaceuticals, Inc. | 41 | 1 |
| Cavion LLC | 42 | 1 |
| Coherus BioSciences, Inc. | 43 | 1 |
| Cortice Biosciences, Inc. | 44 | 1 |
| Eisai Co., Ltd. | 45 | 1 |
| Eli Lilly and Company | 46 | 1 |
| EnGeneIC Ltd | 47 | 1 |
| ERC Belgium SA | 48 | 1 |
| Genzyme Corporation | 49 | 1 |
| GlaxoSmithKline Plc | 50 | 1 |
| GW Pharmaceuticals Plc | 51 | 1 |
| ImmunoCellular Therapeutics, Ltd. | 52 | 1 |
| Inspyr Therapeutics Inc | 53 | 1 |
| Kadmon Corporation, LLC | 54 | 1 |
| Karyopharm Therapeutics, Inc. | 55 | 1 |
| Les Laboratoires Servier SAS | 56 | 1 |
| Medicenna Therapeutics, Inc. | 57 | 1 |
| Merck &Co., Inc. | 58 | 1 |
| Neonc Technologies Inc | 59 | 1 |
| Novartis AG | 60 | 1 |
| Ono Pharmaceutical Co., Ltd. | 61 | 1 |
| Oryx GmbH &Co. KG | 62 | 1 |
| Pfizer Inc. | 63 | 1 |
| StemGen S.p.A | 64 | 1 |
| Stemline Therapeutics, Inc. | 65 | 1 |
| Threshold Pharmaceuticals, Inc. | 66 | 1 |
| Tocagen Inc. | 67 | 1 |
| TRACON Pharmaceuticals Inc | 68 | 1 |
| Upsher-Smith Laboratories, Inc. | 69 | 1 |
| Vascular Biogenics Ltd. | 70 | 1 |
| Vaximm AG | 71 | 1 |
| Virttu Biologics Limited | 72 | 1 |
| Recurrent Glioblastoma Multiforme (GBM) Therapeutics Assessment | 73 | 14 |
| Assessment by Monotherapy Products | 73 | 1 |
| Assessment by Combination Products | 74 | 1 |
| Assessment by Target | 75 | 4 |
| Assessment by Mechanism of Action | 79 | 4 |
| Assessment by Route of Administration | 83 | 2 |
| Assessment by Molecule Type | 85 | 2 |
| Drug Profiles | 87 | 319 |
| (GWP-42002 + GWP-42003) Drug Profile | 87 | 1 |
| abemaciclib Drug Profile | 88 | 5 |
| acalabrutinib Drug Profile | 93 | 3 |
| afatinib dimaleate Drug Profile | 96 | 13 |
| asinercept Drug Profile | 109 | 5 |
| AU-101 Drug Profile | 114 | 1 |
| axitinib Drug Profile | 115 | 6 |
| AXL-1717 Drug Profile | 121 | 2 |
| bevacizumab biosimilar Drug Profile | 123 | 1 |
| BGB-290 Drug Profile | 124 | 2 |
| BLZ-945 Drug Profile | 126 | 2 |
| bosutinib Drug Profile | 128 | 4 |
| buparlisib hydrochloride Drug Profile | 132 | 5 |
| capmatinib Drug Profile | 137 | 3 |
| Cellular Immunotherapy for Glioblastoma Multiforme Drug Profile | 140 | 1 |
| Cellular Immunotherapy for Recurrent Glioblastoma Multiforme Drug Profile | 141 | 1 |
| copper gluconate + disulfiram Drug Profile | 142 | 1 |
| crenolanib besylate Drug Profile | 143 | 3 |
| dacomitinib Drug Profile | 146 | 3 |
| dasatinib Drug Profile | 149 | 3 |
| depatuxizumab mafodotin Drug Profile | 152 | 2 |
| DNX-2401 Drug Profile | 154 | 3 |
| DS-1647 Drug Profile | 157 | 1 |
| ERC-1671 Drug Profile | 158 | 1 |
| evofosfamide Drug Profile | 159 | 14 |
| flucytosine ER + vocimagene amiretrorepvec Drug Profile | 173 | 7 |
| G-200 Drug Profile | 180 | 3 |
| galunisertib Drug Profile | 183 | 3 |
| golvatinib + lenvatinib Drug Profile | 186 | 1 |
| golvatinib tartrate Drug Profile | 187 | 2 |
| GSK-3326595 Drug Profile | 189 | 1 |
| HSV-1716 Drug Profile | 190 | 3 |
| ICT-121 Drug Profile | 193 | 3 |
| infigratinib Drug Profile | 196 | 2 |
| lenvatinib mesylate Drug Profile | 198 | 12 |
| lonafarnib Drug Profile | 210 | 2 |
| M-032 Drug Profile | 212 | 1 |
| MDNA-55 Drug Profile | 213 | 1 |
| mibefradil dihydrochloride Drug Profile | 214 | 3 |
| mipsagargin Drug Profile | 217 | 5 |
| nabiximols Drug Profile | 222 | 7 |
| napabucasin Drug Profile | 229 | 6 |
| NEO-100 Drug Profile | 235 | 2 |
| nilotinib Drug Profile | 237 | 6 |
| nivolumab Drug Profile | 243 | 32 |
| ofranergene obadenovec Drug Profile | 275 | 6 |
| ONC-201 Drug Profile | 281 | 5 |
| Oncolytic Virus to Target Carcinoembryonic Antigen for Oncology Drug Profile | 286 | 1 |
| OS-2966 Drug Profile | 287 | 2 |
| p28 Drug Profile | 289 | 2 |
| paclitaxel trevatide Drug Profile | 291 | 4 |
| Parvoryx Drug Profile | 295 | 2 |
| pazopanib hydrochloride Drug Profile | 297 | 7 |
| pembrolizumab Drug Profile | 304 | 31 |
| Recombinant Protein to Agonize BMPR1A, BMPR1B and BMPR2 for Colorectal Cancer and Glioblastoma Multiforme Drug Profile | 335 | 1 |
| rilotumumab Drug Profile | 336 | 2 |
| S-49076 Drug Profile | 338 | 1 |
| selinexor Drug Profile | 339 | 18 |
| SGT-53 Drug Profile | 357 | 2 |
| SL-701 Drug Profile | 359 | 2 |
| sonidegib phosphate Drug Profile | 361 | 4 |
| tesevatinib tosylate Drug Profile | 365 | 3 |
| TPI-287 Drug Profile | 368 | 4 |
| TRC-102 Drug Profile | 372 | 2 |
| TRC-105 Drug Profile | 374 | 8 |
| trebananib Drug Profile | 382 | 3 |
| urelumab Drug Profile | 385 | 2 |
| USL-311 Drug Profile | 387 | 1 |
| Vaccine for Recurrent Glioblastoma Multiforme Drug Profile | 388 | 1 |
| Vaccine to Target CD155/NECL5 for Recurrent Glioblastoma Multiforme Drug Profile | 389 | 1 |
| vandetanib Drug Profile | 390 | 7 |
| VEDVDox Drug Profile | 397 | 2 |
| vorinostat Drug Profile | 399 | 4 |
| VXM-01 Drug Profile | 403 | 3 |
| Recurrent Glioblastoma Multiforme (GBM) Dormant Projects | 406 | 2 |
| Recurrent Glioblastoma Multiforme (GBM) Discontinued Products | 408 | 1 |
| Recurrent Glioblastoma Multiforme (GBM) Product Development Milestones | 409 | 10 |
| Featured News &Press Releases | 409 | 1 |
| Sep 26, 2016: Cavion to Present Clinical Trial Preliminary Results at ASTRO | 409 | 1 |
| Aug 29, 2016: Kadmon Initiates Phase 2 Clinical Trial Evaluating Tesevatinib in Glioblastoma | 409 | 1 |
| Jul 27, 2016: DNAtrix Receives European Medicines Agency PRIME Designation | 410 | 1 |
| Jul 25, 2016: ImmunoCellular Therapeutics Provides Update on Lead Cancer Immunotherapy ICT-121 | 410 | 1 |
| Jul 21, 2016: DNAtrix Announces Successful Intratumoral Delivery of DNX-2401 via Alcyone s MEMS Cannula for the Targeted Treatment of Recurrent Glioblastoma | 410 | 1 |
| Jun 05, 2016: AbbVie Presents Encouraging Phase 1 Data for Investigational Medicine ABT-414 as Monotherapy in Patients with an Aggressive Brain Cancer at the 2016 American Society of Clinical Oncology Annual Meeting | 411 | 1 |
| Jun 03, 2016: Clinical Data Presented at ASCO Demonstrate Significant Overall Survival Benefit in rGBM Patients Receiving VB-111 Compared with Historical Avastin Meta-analysis Data | 412 | 1 |
| Jun 03, 2016: Cortice Biosciences Announces Presentation of Results from a Phase 1/2 Clinical Trial Evaluating TPI 287 for Treatment of Recurrent Glioblastoma at the Annual Meeting of the American Society of Clinical Oncology | 413 | 1 |
| May 18, 2016: AbbVie To Present Data on ABT-414 at ASCO 2016 | 414 | 1 |
| May 18, 2016: Karyopharm to Present Selinexor Clinical Data at the American Society of Clinical Oncology Annual Meeting | 415 | 1 |
| Feb 22, 2016: VBL Therapeutics Announces Launch of the First Israeli Site as Part of the GLOBE International Pivotal Trial for VB-111 | 416 | 1 |
| Feb 16, 2016: Apogenix Receives EUR3 Million Grant for the Development of a Companion Diagnostic Test for Lead Immuno-Oncology Candidate APG101 | 417 | 1 |
| Feb 10, 2016: Daiichi Sankyo Joint Development Product Designated Under SAKIGAKE Designation System | 417 | 1 |
| Jan 21, 2016: Oncoceutics Begins Fifth Clinical Trial for ONC201 | 418 | 1 |
| Jan 14, 2016: Apogenix Strengthens U.S. Patent Position for Lead Immuno-Oncology Candidate APG101 | 418 | 1 |
| Appendix | 419 | 2 |
| Methodology | 419 | 1 |
| Coverage | 419 | 1 |
| Secondary Research | 419 | 1 |
| Primary Research | 419 | 1 |
| Expert Panel Validation | 419 | 1 |
| Contact Us | 419 | 1 |
| Disclaimer | 420 | 1 |